Daniel Grosslight
Stock Analyst at Citigroup
(1.17)
# 3,710
Out of 5,182 analysts
126
Total ratings
33.33%
Success rate
-14.6%
Average return
Main Sectors:
Stocks Rated by Daniel Grosslight
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHR Phreesia | Downgrades: Neutral | $25 → $10 | $8.09 | +23.61% | 9 | Mar 31, 2026 | |
| HCAT Health Catalyst | Maintains: Neutral | $2.75 → $1.75 | $1.01 | +73.27% | 13 | Mar 13, 2026 | |
| HIMS Hims & Hers Health | Upgrades: Neutral | $13 → $24 | $19.75 | +21.52% | 14 | Mar 10, 2026 | |
| TDOC Teladoc Health | Maintains: Neutral | $9 → $6 | $5.25 | +14.29% | 14 | Mar 3, 2026 | |
| PRVA Privia Health Group | Maintains: Buy | $34 → $32 | $22.71 | +40.91% | 2 | Mar 3, 2026 | |
| GDRX GoodRx Holdings | Maintains: Buy | $4.5 → $3.5 | $2.16 | +62.04% | 9 | Mar 3, 2026 | |
| AGL agilon health | Maintains: Neutral | $21 → $19 | $19.84 | -5.49% | 7 | Mar 3, 2026 | |
| EVH Evolent Health | Maintains: Buy | $6 → $4 | $2.44 | +63.93% | 7 | Feb 26, 2026 | |
| CTEV Claritev | Maintains: Buy | $63 → $21 | $17.88 | +17.45% | 5 | Feb 25, 2026 | |
| WAY Waystar Holding | Maintains: Buy | $46 → $35 | $21.81 | +60.48% | 4 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $4 | $2.63 | +52.09% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $190 → $244 | $215.80 | +13.07% | 11 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $820 → $860 | $873.43 | -1.54% | 8 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $10 | $1.32 | +657.58% | 7 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $8 | $9.33 | -14.26% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.25 | $0.69 | +81.16% | 5 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $7 → $3.5 | $5.17 | -32.24% | 2 | Nov 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $12.22 | +6.38% | 1 | Dec 11, 2019 |
Phreesia
Mar 31, 2026
Downgrades: Neutral
Price Target: $25 → $10
Current: $8.09
Upside: +23.61%
Health Catalyst
Mar 13, 2026
Maintains: Neutral
Price Target: $2.75 → $1.75
Current: $1.01
Upside: +73.27%
Hims & Hers Health
Mar 10, 2026
Upgrades: Neutral
Price Target: $13 → $24
Current: $19.75
Upside: +21.52%
Teladoc Health
Mar 3, 2026
Maintains: Neutral
Price Target: $9 → $6
Current: $5.25
Upside: +14.29%
Privia Health Group
Mar 3, 2026
Maintains: Buy
Price Target: $34 → $32
Current: $22.71
Upside: +40.91%
GoodRx Holdings
Mar 3, 2026
Maintains: Buy
Price Target: $4.5 → $3.5
Current: $2.16
Upside: +62.04%
agilon health
Mar 3, 2026
Maintains: Neutral
Price Target: $21 → $19
Current: $19.84
Upside: -5.49%
Evolent Health
Feb 26, 2026
Maintains: Buy
Price Target: $6 → $4
Current: $2.44
Upside: +63.93%
Claritev
Feb 25, 2026
Maintains: Buy
Price Target: $63 → $21
Current: $17.88
Upside: +17.45%
Waystar Holding
Feb 18, 2026
Maintains: Buy
Price Target: $46 → $35
Current: $21.81
Upside: +60.48%
Jan 9, 2026
Maintains: Buy
Price Target: $7 → $4
Current: $2.63
Upside: +52.09%
Jan 9, 2026
Upgrades: Buy
Price Target: $190 → $244
Current: $215.80
Upside: +13.07%
Sep 24, 2025
Maintains: Buy
Price Target: $820 → $860
Current: $873.43
Upside: -1.54%
Aug 9, 2023
Maintains: Neutral
Price Target: $9 → $10
Current: $1.32
Upside: +657.58%
Aug 4, 2023
Downgrades: Sell
Price Target: $7 → $8
Current: $9.33
Upside: -14.26%
Apr 28, 2023
Maintains: Neutral
Price Target: $1.5 → $1.25
Current: $0.69
Upside: +81.16%
Nov 16, 2021
Downgrades: Neutral
Price Target: $7 → $3.5
Current: $5.17
Upside: -32.24%
Dec 11, 2019
Initiates: Outperform
Price Target: $13
Current: $12.22
Upside: +6.38%